Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erik Shaw

Physical Medicine & Rehabilitation Atlanta, GA Doctor of Osteopathy

NPI 1821023359 CMS profile 263661

2020 Peachtree Rd Nw, Atlanta, GA 30309

Open in the dashboard

General payments

$174,556

368 records reported · program years 2019–2025

Research payments

$5,320

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$142,077 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Erik Shaw of Atlanta, GA is reported in the CMS Open Payments database as having received $174,556 across 368 general payments and $5,320 in research payments paid to them. Separately, studies naming them as principal investigator received $142,077 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,576 24
2024 General $10,692 40
2023 General $16,063 56
2022 General $25,918 54
2021 General $24,646 40
2021 Research $3,980 2
2020 General $19,661 22
2020 Research $1,270 2
2019 General $66,000 132
2019 Research $70 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erik Shaw
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Erik Shaw were reported at $11,576. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Erik Shaw Physical Medicine & Rehabilitation median Middle half National median
2019 $66,000 $133 $45–$390 $163
2020 $19,661 $88 $29–$272 $114
2021 $24,646 $116 $33–$360 $132
2022 $25,918 $123 $40–$378 $149
2023 $16,063 $131 $43–$396 $160
2024 $10,692 $141 $45–$409 $164
2025 $11,576 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biodelivery Sciences International, Inc. $43,696 53 payments
  2. Boston Scientific Corporation $30,136 60 payments
  3. Nalu Medical, Inc. $24,184 51 payments
  4. TerSera Therapeutics LLC $22,474 34 payments
  5. SPR Therapeutics, Inc $20,550 38 payments
  6. Pfizer Inc. $11,773 9 payments
  7. Collegium Pharmaceutical, Inc. $10,529 6 payments
  8. Lilly USA, LLC $5,158 25 payments
  9. RedHill Biopharma Inc. $2,080 1 payment
  10. Pacira Pharmaceuticals Incorporated $1,154 12 payments
  11. Other $2,822 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $59,222 27 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,793 33 payments
  3. Honoraria $30,730 12 payments
  4. Food and Beverage $16,289 244 payments
  5. Travel and Lodging $9,522 52 payments
Products named General payments · program years 2019–2025
  1. BELBUCA Addiction Therapy $27,512 30 payments
  2. Nalu Neurostimulation System $24,184 51 payments
  3. SPRINT PNS System $20,550 38 payments
  4. BELBUCA Chronic Pain $16,160 20 payments
  5. PRIALT $15,282 23 payments
  6. SYMPROIC $11,263 12 payments
  7. XTAMPZA $10,529 6 payments
  8. BELBUCA Opioid Analgesic $10,489 5 payments
  9. SPECTRA WAVEWRITER $10,278 7 payments
  10. WaveWriter Alpha Prime 16 $9,295 21 payments
  11. Other $24,257 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $5,250 4 payments
  2. Saluda Medical Americas, Inc. $70 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,645

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$244,255

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

50.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 81 $77,787
Nucynta Er Tapentadol Hcl Brand 48 $52,338
Nucynta Tapentadol Hcl Brand 30 $33,758
Buprenorphine Generic 91 $23,459
Linzess Linaclotide Brand 15 $15,530
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 319 $11,830
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 302 $6,279
Xtampza Er Oxycodone Myristate Brand 11 $4,058
Oxycodone Hcl Generic 161 $2,834
Sumatriptan Succinate Generic 13 $2,527

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$33,522

Medicare's payments for the services billed

Medicare patients

175

Average age 68

Services billed

524

91 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 46%
Diabetes 26%
Ischemic heart disease 25%
Osteoporosis 18%
Atrial fibrillation 17%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $3,625
$3,625 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $802
$802 — —
Xeomin
  • Merz Pharmaceuticals, LLC $79
$79 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $38
$38 11 —
BOTOX
  • AbbVie, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record